American Healthcare REIT Reports Strong 2025 Results, Raises 2026 Guidance, and Secures Over $1.1B in Equity Capital for Growth
Summary
American Healthcare REIT reported strong Q4 and full-year 2025 results, including double-digit Same-Store NOI growth and a 22% increase in NFFO per share, alongside robust 2026 guidance and over $1.1 billion in equity capital raises to fund strategic acquisitions and development.
Key Events
-
Strong Q4 and Full Year 2025 Financial Results
The company reported GAAP net income of $69.8 million for the full year 2025 and Normalized Funds from Operations (NFFO) of $1.72 per diluted share, representing 22% growth over the prior year. Total portfolio Same-Store Net Operating Income (NOI) grew by 14.2% for the year.
-
Positive Full Year 2026 Guidance Issued
American Healthcare REIT issued NFFO per diluted share guidance of $1.99 to $2.05 for 2026, a significant increase from 2025's $1.72. Total portfolio Same-Store NOI growth is projected to be between 7.0% and 11.0%.
-
Substantial Equity Capital Raises
The company successfully raised approximately $275.1 million and $32.5 million through its At-The-Market (ATM) program in Q4 2025. Additionally, it entered into new forward sale agreements for approximately $361.7 million via the ATM program and completed a forward follow-on common equity offering for approximately $447.1 million, totaling over $1.1 billion in capital raised or committed.
-
Strategic Acquisitions and Development Funding
Over $950 million in new investments were purchased in 2025, with an additional $117.5 million in SHOP assets acquired subsequent to year-end. The capital raises are intended to fully fund these acquisitions and the company's in-process development pipeline.
Analysis
This 8-K is highly important as it details American Healthcare REIT's strong financial performance for 2025, marked by significant Same-Store NOI and NFFO per share growth. The company also provided an optimistic outlook for 2026 with substantial NFFO per share guidance. Critically, the REIT successfully raised over $1.1 billion in equity capital through various offerings, strategically leveraging its stock trading near 52-week highs to fund over $1 billion in new acquisitions and its development pipeline. This capital infusion, coupled with an improved debt-to-EBITDA ratio, significantly strengthens the company's balance sheet and provides a clear runway for continued growth in the healthcare real estate sector. Investors should view this as a strong signal of operational execution and strategic financial management.
At the time of this filing, AHR was trading at $52.55 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $26.48 to $53.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.